RALEIGH, N.C., Feb. 28, 2022 /PRNewswire/ -- ERGOMED
plc (LSE: ERGO) a leading Clinical Research
Organization focused on rare disease drug development today
announced the establishment of its Rare Disease Innovation
Center.
Rare diseases impact around 300 million people worldwide. For
each disease, clinical trial sponsors face major challenges due to
the rarity of patients, coupled with issues such as a limited pool
of experience investigators, heterogeneity of indication, lack of
established endpoints, and poorly understood natural history.
The Rare Disease Innovation Center™ is a consortium of
innovative industry-leading partners and internal subject matter
experts dedicated to developing tailored and innovative solutions
for rare disease focused companies and patients.
ERGOMED's Rare Disease Innovation Center™ will provide best in
class global solutions to address the challenges faced by rare
disease sponsors to help them reduce clinical trial timelines,
optimize patient experience, and bring effective rare disease
therapies to market more quickly. The Rare Disease Innovation
Center™ will also utilize ERGOMED's Site Advantage™ operating
model, specifically designed to provide specialized support to
research sites and patients participating in rare disease clinical
research.
"Rare disease drug development is the fastest growing area in
drug development with a 12-14% annual growth rate, accounting for
about one third of the drugs in development. We're excited about
the opportunity to launch our Rare Disease Innovation Center to
leverage ERGOMED's experience from doing hundreds of rare disease
studies in conjunction with innovative approaches from our industry
partners to help our sponsors overcome challenges in rare disease
drug development," said Zizi
Uzezi Imatorbhebhe, MBA, MS, PMP®, Senior Vice President, Global
Strategy and Development, Head Rare Disease Innovation Center,
ERGOMED.
The ERGOMED Rare Disease Innovation Center™ will help
biotechnology and pharma sponsors focused on rare disease:
- Strategically guide and plan their rare disease drug
development program to avoid pitfalls and leverage innovative
approaches
- Design more intelligent clinical trials by optimizing their
protocol, trial design, assessing study feasibility and performance
analytics to predict key milestones and scenario analyses
- Adopt the right innovations such as decentralization and other
technologies to identify and retain rare disease patients
- Leverage its ERGOMED Patient
First™ approach to reduce patient burden in clinical trial
participation and ensure that the voice of the patient is captured
and incorporated throughout the clinical development lifecycle
- Utilize Real World Evidence for synthetic control arms, patient
selection, biomarkers, end point selection, patient registries and
other areas
The Rare Disease Innovation Center™ includes several key
innovative partners such as Trial Bee, mdgroup,
THREAD™, Clinone, Medidata, a Dassault Systèmes company,
Rare Patient Voice, Patient Wing and others.
"Rare disease is a strategic focus for ERGOMED and we are
glad to support our customers through the Rare Disease Innovation
Center," said Gordana Tonkovic, MD President, ERGOMED
About ERGOMED
Founded in 1997, ERGOMED plc is
dedicated to the provision of specialized services to the
pharmaceutical industry and the development of new drugs. With a
global footprint covering 100+ countries, we have the reach to
deliver solutions for even the toughest clinical development and
trial management challenges.
ERGOMED has provided clinical
development, trial management, and pharmacovigilance services for
300+ clients, from top 10 pharmaceutical and generics organizations
to small and mid-sized drug development companies.
For more information visit www.ergomedcro.com or email
rareinnovate@ergomedplc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ergomed-announces-launch-of-its-rare-disease-innovation-center-301491490.html
SOURCE ERGOMED